Lirum Therapeutics, Inc. Sample Contracts
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 18th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LIRUM THERAPEUTICS, INC.Pre-Funded Common Stock Purchase Warrant • June 28th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lirum Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several UnderwritersUnderwriting Agreement • June 28th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 22nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
EMPLOYMENT AGREEMENTEmployment Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 17, 2023 (the “Effective Date”) by and between Peter McDonald (“Employee”) and Lirum Therapeutics, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Parties.”
SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this 11th day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
This license agreement (this “Agreement”) is entered into as of January 12, 2022 (the “Effective Date”) by and between IGF Oncology, LLC, a Delaware limited liability company, having an address of 7460 Pinehurst Road, Saint Paul, MN 55115 (“IGF”) and Lirum Therapeutics, Inc. a Delaware corporation, having an address of 590 Park Avenue, New York, NY 10065 (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
THIRD AMENDMENT TO the LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to the License Agreement (this “Third Amendment”) is made and entered into this 12th day of January 2024, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
FIRST AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to the License Agreement (this “First Amendment”) is made and entered into this 11th day of January 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.